Novartis Boosts HCV Portfolio With First-in-Class Debiopharm Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
Hepatitis C sector heats up as Novartis gains rights to Debiopharm's leading cyclophilin inhibitor